Anxiety and depression levels in interferon using and non using hepatitis C patients;Interferon tedavisi alan ve almayan hepatit C hastalarinda anksiyete ve depresyon düzeyleri

Klinik Psikofarmakoloji Bulteni

Volumn 16, Issue 3, 2006, Pages 155-159

  Yumru, Mehmet ^a   Sirmatel, Fatma ^a,b   Virit, Osman ^a   Savaş, Esen ^c   Savaş, Haluk A ^a   Herken, Hasan ^a,d  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b HARRAN UNIVERSITY   (Turkey)

^c Av Cengiz Gökçek Devlet Hastanesi Dahiliye Birimi ^*

^d PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Anxiety; Depression; Hepatitis C; Interferon

Indexed keywords

INTERFERON;

ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEPATITIS C; HUMAN;

EID: 33749519988     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26: 62-65
2. Tong MJ, el Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466
3. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP. Long term mortality after transfusion associated non A, non B, hepatitis. The National Heart, Lung and Blood Institue Study Group. N Engl J Med 1992;327: 1906-1911
4. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza Cr, Dusheiko GM, Lee CA, Ludlam CA, Preston FE. Mortality from liver cancer and liver disease in hemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350: 1425-1431
5. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA. Psychiatric complication of long-term alpha therapy. Arch Intern Med. 1987;147: 1577-1580
6. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis. 1989;9: 273-277
7. Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C. An overview of cases in Japan. Psychiatry Clin Neurosci 1997;51: 175-180
8. el- Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002;123: 476-482
9. Kalyoncu OA, Tan D, Mirsal H, Pektas O, Beyazyurek M. Major depressive disorder with psychotic features induced by interferon-alpha treatment for hepatitis C in a polydrug abuser. J Psychopharmacol. 2005;19: 102-105
10. Tamam L, Yerdelen D, Ozpoyraz N. Psychosis associated with interferon alfa therapy for chronic hepatitis B. Ann Pharmacother. 2003;37: 384-387
11. Kraus MR, Schafer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000;41: 377-384
12. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000;49: 311-317
13. Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997;42: 186-191
14. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44: 104-112
15. Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Vargas V, Estepan R, Guardia J. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003;39: 231-238
16. Coughlan B, Sheehan J, Hickey A, Crowe J. Psychological well-being and quality of life in women with an iatrogenic hepatitis C virus infection. Br J Health Psychol 2002;7: 105-116
17. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27: 209-212
18. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30: 1299-1301
19. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64: 708-714
20. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors.Gen Hosp Psychiatry. 2005;27: 431-438
21. Goulding C, O'Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 2001;13: 507-511
22. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis. Psychiatr Clin Neurosci 2000; 54: 565-572
23. Smith A, Tyrrell D, Coyle K, Higgins P. Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology (Berl) 1988;96: 414-416
24. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93: 785-789
25. Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychologic distress and depression in patients with endstage liver disease due to hepatitis C virus. Clin Transplant 1997;11: 406-411
26. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-_ treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42: 2482-2486
27. Pariante C, Orru M, Baita A, Farci M, Carpiniello B. Treatment with interferon-_ in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999;354: 131-132
28. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review Am J Psychiatry 2000;157: 867-876
29. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric Adverse Effects of Interferon-_: CNS Drugs. 2005;19: 105-123
30. Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 1986;57: 1709-1715
31. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer H Jr, Perrillo R, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321: 1501-1510
32. Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression: a computed tomographic study. Arch Gen Psychiatry 1992;49: 384-387
33. Preziati D, La Rossa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.Eur J Endocrinol 1995;132: 587-593
34. Lieb K, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Janssen G, Schaefer M. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry. 2006;21: 204-210
35. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993;88: 760-761
36. Goldman LS. Successful treatment of interferon-alpha induced mood disorder with nortriptyline (letter). Psychosomatics 1994;35: 412-413
37. Kraus MR, Schafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. Journal of Viral Hepatitis, 2005;12: 96-100